Quick Comparison
| P21 (P021) | Thymosin Beta-4 | |
|---|---|---|
| Half-Life | 4-6 hours (limited pharmacokinetic data) | 1-2 hours |
| Typical Dosage | Research/user-reported: 1-2 mg intranasal or subcutaneous once daily. No established clinical dosing protocol. Often cycled 4-8 weeks on, 2-4 weeks off. | Loading: 750 mcg-2 mg subcutaneous two or three times weekly for 2-4 weeks. Maintenance: 750 mcg-2 mg subcutaneous once or twice weekly. Some protocols use higher loading doses for acute injuries. |
| Administration | Intranasal or subcutaneous injection | Subcutaneous injection |
| Research Papers | 0 papers | 30 papers |
| Categories |
Mechanism of Action
P21 (P021)
P21 (P021) is a small molecule peptide mimetic derived from ciliary neurotrophic factor (CNTF), a neurotrophic cytokine that supports neuronal survival and differentiation. Full-length CNTF has potent neurotrophic effects but cannot be used therapeutically because it causes severe cachexia (weight loss), fever, and inflammatory responses through its systemic actions on the gp130/LIFRβ/CNTFRα receptor complex in peripheral tissues. P21 was designed to capture the neurotrophic activity while being small enough to cross the blood-brain barrier and avoiding the systemic side effects.
P21's primary mechanism in promoting neurogenesis involves upregulation of BDNF expression in the hippocampal dentate gyrus — one of the two brain regions where adult neurogenesis occurs. BDNF promotes the proliferation of neural progenitor cells in the subgranular zone, their differentiation into mature neurons, and the survival and integration of these newborn neurons into existing hippocampal circuits. Enhanced neurogenesis in the dentate gyrus is directly associated with improved pattern separation, spatial memory, and cognitive flexibility — functions that deteriorate in aging and Alzheimer's disease.
P21's second major mechanism is inhibition of glycogen synthase kinase-3 beta (GSK-3β), one of the primary kinases responsible for pathological tau hyperphosphorylation in Alzheimer's disease. Under normal conditions, tau protein stabilizes microtubules in neuronal axons, supporting axonal transport. GSK-3β hyperactivity leads to excessive tau phosphorylation at multiple serine/threonine residues, causing tau to detach from microtubules and aggregate into neurofibrillary tangles — one of the two hallmark pathologies of Alzheimer's disease (alongside amyloid plaques). By inhibiting GSK-3β, P21 reduces tau hyperphosphorylation, prevents tangle formation, and maintains microtubule stability and axonal transport. In preclinical studies with Alzheimer's model mice, P21 treatment rescued cognitive deficits, increased neurogenesis, and reduced tau pathology, suggesting disease-modifying potential rather than merely symptomatic relief.
Thymosin Beta-4
Thymosin Beta-4 (Tβ4) is a 43-amino-acid peptide and the most abundant member of the beta-thymosin family. Despite its name (derived from its original isolation from thymus tissue), Tβ4 is expressed in virtually every nucleated cell in the body and is particularly concentrated in platelets, wound fluid, and developing tissues. TB-500 is the commercially available active fragment.
The primary molecular function is G-actin sequestration. Tβ4 binds globular actin (G-actin) monomers at a 1:1 stoichiometric ratio through a central actin-binding domain (LKKTET motif), maintaining a large intracellular pool of unpolymerized actin available for rapid mobilization. When cells need to migrate — as during wound healing, inflammation, or development — Tβ4 releases G-actin for polymerization into filamentous actin (F-actin) at the cell's leading edge. This dynamic actin cycling is the fundamental force-generating mechanism for cell migration.
Beyond actin regulation, Tβ4 has extensive signaling functions. It promotes angiogenesis by stimulating endothelial cell migration, tubule formation, and the expression of VEGF and angiopoietin-1. It reduces inflammation by modulating NF-κB signaling, decreasing production of TNF-α, IL-1β, and other pro-inflammatory mediators. In wound healing, Tβ4 upregulates laminin-5 production — a key component of the basement membrane that guides epithelial cell migration during wound re-epithelialization. It activates cardiac progenitor cells and promotes cardiomyocyte survival following ischemic injury, an effect that has generated significant interest for cardiac repair applications.
Tβ4 also promotes stem cell migration and differentiation through activation of the Akt cell survival pathway. It stimulates hair follicle stem cell migration and differentiation, which has been observed as increased hair growth in animal studies. The combination of cell migration, angiogenesis, anti-inflammation, stem cell activation, and extracellular matrix remodeling makes Tβ4 one of the most comprehensive endogenous healing molecules identified.
Risks & Safety
P21 (P021)
Common
headache, nasal irritation (intranasal route), mild fatigue.
Serious
very limited human safety data, no long-term data on effects on brain tissue.
Rare
allergic reactions.
Thymosin Beta-4
Common
injection site irritation, headache, nausea, temporary fatigue.
Serious
may promote existing tumors by stimulating new blood vessel formation and cell movement, no long-term data on effects on tissue remodeling.
Rare
allergic reactions, localized infection.
Full Profiles
P21 (P021) →
A small peptide derived from a brain-protecting factor (CNTF). Helps create new brain cells, protects existing neurons, and blocks the process that forms tangles in Alzheimer's disease. One of the few peptides specifically targeting brain degeneration, with potential for Alzheimer's disease and age-related cognitive decline.
Thymosin Beta-4 →
The full-length 43-amino-acid peptide naturally produced by the thymus gland — the parent molecule from which TB-500 is derived. Plays a key role in cell movement, tissue repair, wound healing, and reducing inflammation throughout the body. The full-length form may offer broader healing benefits than the TB-500 fragment alone.